GT Biopharma Inc
Change company Symbol lookup
Select an option...
GTBP GT Biopharma Inc
HTGC Hercules Capital Inc
MPW Medical Properties Trust Inc
ST Sensata Technologies Holding PLC
ZTS Zoetis Inc
AZZ AZZ Inc
CRM Salesforce Inc
IVR-C Invesco Mortgage Capital Inc
MSM MSC Industrial Direct Co Inc
BLUE bluebird bio Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The Company's TriKE platform generate therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer (NK) cells. GTB-3550 is the Company's TriKE product candidate, which is a single-chain, tri-specific recombinant fusion protein construct consisting of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The Company is focused on studying this anti-CD16-IL-15-anti-CD33 TriKE in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS).

Closing Price
$3.07
Day's Change
0.19 (6.60%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.07
Day's Low
2.77
Volume
(Light)
Volume:
152,951

10-day average volume:
393,307
152,951
  • Prev Close
    2.88
  • Today's Open
    2.77
  • Day's Range
    2.77-3.07
  • Avg Vol (10-day)
    393.3K
  • Last (time)
    4:00p ET 07/05/22
  • Last (size)
    4
  • 52-Wk Range
    1.51 - 15.44
    LowHigh
  • (07/06/21 - 05/06/22)
    103.31%
  • 89.1%
  • Market Cap
    93.6M
  • Shares Outstanding
    30.5M
  • -1.00
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.5
  • 13.98
  • (% of float 06/15/22)
    5.61

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.